Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Cabazitaxel

Nature Reviews Drug Discovery volume 9, pages 677–678 (2010)Cite this article

Subjects

In June 2010, the taxane anticancer drug cabazitaxel (Jevtana; Sanofi–Aventis), in combination with prednisone, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with hormone-refractory metastatic prostate cancer who had been previously treated with a regimen containing the taxane docetaxel.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Taxane anticancer drugs.

References

  1. Jemal, A. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

    Article  Google Scholar 

  2. Oh, W. K. & Schurko, B. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nature Clin. Pract. Oncol. 5, 506–507 (2008).

    Article  Google Scholar 

  3. Higano, C. S. et al. Sipuleucel-T. Nature Rev. Drug Discov. 9, 513–514 (2010).

    Article  CAS  Google Scholar 

  4. Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nature Rev. Cancer 4, 253–265 (2004).

    Article  CAS  Google Scholar 

  5. Mita, A. C. et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 15, 723–730 (2009).

    Article  CAS  Google Scholar 

  6. Pivot, X. et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol. 19, 1547–1552 (2008).

    Article  CAS  Google Scholar 

  7. US Food and Drug Administration. FDA labelling information — Jevtana (cabazitaxel). FDA website [online], (2010).

  8. De Bono, J. S. et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). J. Clin. Oncol. 28 (Suppl. 15), 4508 (2010).

    Article  Google Scholar 

  9. Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447–4454 (2008).

    Article  CAS  Google Scholar 

  10. Locke, J. A. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68, 6407–6415 (2008).

    Article  CAS  Google Scholar 

  11. Danila, D. C. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28, 1496–1501 (2010).

    Article  CAS  Google Scholar 

  12. Reid, A. H. et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489–1495 (2010).

    Article  CAS  Google Scholar 

  13. Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375, 1437–1446 (2010).

    Article  CAS  Google Scholar 

  14. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).

    Article  CAS  Google Scholar 

  15. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).

    Article  CAS  Google Scholar 

  16. IMS MIDAS (IMS Health, 2010).

  17. Hauber, A. et al. JP Morgan Europe Research (JP Morgan Cazenove, 21 May 2010).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Matthew D. Galsky and William K. Oh are at the Mount Sinai School of Medicine, Box 1079, One Gustave L. Levy Place, New York, New York 10029-6574, USA. matthew.galsky@mssm.edu; william.oh@mssm.edu,

    Matthew D. Galsky & William K. Oh

  2. Argyris Dritselis is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. ADritselis@be.imshealth.com,

    Argyris Dritselis

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Matthew D. Galsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Argyris Dritselis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William K. Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

W.K.O has received research funding from Sanofi-Aventis and Genentech, and has acted as a consultant for Amgen, Centocor, Genentech and Bellicum.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galsky, M., Dritselis, A., Kirkpatrick, P. et al. Cabazitaxel. Nat Rev Drug Discov 9, 677–678 (2010). https://doi.org/10.1038/nrd3254

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3254

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research